<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Genomics</journal-id><journal-title>BMC Genomics</journal-title><issn pub-type="epub">1471-2164</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2164-9-403</article-id><article-id pub-id-type="pmid">18755030</article-id><article-id pub-id-type="doi">10.1186/1471-2164-9-403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Hepatocyte RXRalpha deficiency in matured and aged mice: impact on the expression of cancer-related hepatic genes in a gender-specific manner</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Guo</surname><given-names>Minglei</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mguo@kumc.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Gong</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>lei.gong@bms.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>He</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lhe@kumc.edu</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Lehman-McKeeman</surname><given-names>Lois</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Lois.Lehman-McKeeman@bms.com</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Wan</surname><given-names>Yu-Jui Yvonne</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ywan@kumc.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Pharmacology, Toxicology &#x00026; Therapeutics, University of Kansas Medical Center, Kansas City, KS, 66103, USA</aff><aff id="I2"><label>2</label>Discovery Toxicology, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>28</day><month>8</month><year>2008</year></pub-date><volume>9</volume><fpage>403</fpage><lpage>403</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2164/9/403"/><history><date date-type="received"><day>1</day><month>4</month><year>2008</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Guo et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>Guo et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Guo Minglei mguo@kumc.edu </dc:author><dc:title> Hepatocyte RXRalpha deficiency in matured and aged mice: impact on the expression of cancer-related hepatic genes in a gender-specific manner </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Genomics 9(1): 403-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2164(2008)9:1&#x0003c;403&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2164</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The occurrence of liver cancer is higher in males than in females, and the incidence increases during aging. Signaling pathways regulated by retinoid &#x000d7; receptor &#x003b1; (RXR&#x003b1;) are involved in hepatocellular carcinogenesis. The phenotype of hepatocyte RXR&#x003b1; deficient mice is different between genders. To explore the impact of hepatocyte RXR&#x003b1; deficiency on gender-dependent hepatic gene expression, we compared the expression profiles of cancer-related genes in 6 and 24 month old male and female mice.</p></sec><sec><title>Results</title><p>In 6 month old mice, male mutant mice showed more cancer-related genes with alteration in mRNA levels than females did (195 vs. 60). In aged mice (24 month), female mutant mice showed greater deviation in mRNA expression levels of cancer-related genes than their male counterparts (149 vs. 82). The genes were classified into five categories according to their role in carcinogenesis: apoptosis, metastasis, cell growth, stress, and immune respnse. In each category, dependent upon age and gender, the genes as well as the number of genes with altered mRNA levels due to RXR&#x003b1; deficiency varies.</p></sec><sec><title>Conclusion</title><p>The change in hepatic cancer-related gene expression profiles due to RXR&#x003b1; deficiency was gender- and age-dependent. The alteration of mRNA levels of cancer-related genes implied that aberrant RXR&#x003b1; signaling could potentially increase the risk of liver cancer and that retinoid signaling might contribute to gender- and age-associated liver cancer incidence.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>RXRs (Retinoid &#x000d7; Receptors), belonging to the nuclear receptor superfamily, play important roles in detoxification, apoptosis, differentiation, and proliferation through hetero-dimerizing with other nuclear receptors [<xref ref-type="bibr" rid="B1">1</xref>]. RXR &#x003b1;, &#x003b2;, and &#x003b3; are the receptors for retinoids, and have been used to prevent and treat cancer. RXR&#x003b1; is the most prevalent receptor expressed in liver. Aberrant RXR&#x003b1;-induced pathways have been implicated as possible mechanisms for the development of hepatocellular carcinoma [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Hepatocyte-specific RXR&#x003b1;-deficient mice were first generated by Wan etc. [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Although hepatocyte RXR&#x003b1; deficiency does not show an obvious phenotype, many metabolic pathways including fatty acid, cholesterol, and xenobiotic are compromised due to hepatocyte RXR&#x003b1; deficiency. Furthermore, shortened hepatocyte lifespan and impaired capacity for liver regeneration after partial hepatectomy are detected in hepatocytes that do not express RXR&#x003b1; [<xref ref-type="bibr" rid="B6">6</xref>]. These findings indicate that hepatocyte RXR&#x003b1; is not only important for liver metabolism, but also in control of hepatocyte proliferation and survival.</p><p>The impact of RXR&#x003b1; deficiency on the expression of RXR&#x003b1; target genes is gender dependent. The expression of cytochrome P450 (CYP450) genes including Cyp4a, 3a, and 2b are differentially expressed in male and female hepatocyte RXR&#x003b1;-deficient mice [<xref ref-type="bibr" rid="B7">7</xref>]. Using sex hormone treatments, we have previously shown that male hormones might have an impact on regulating RXR&#x003b1;-mediated signaling [<xref ref-type="bibr" rid="B7">7</xref>]. In addition to gender, aging also imposes significant changes on nuclear receptor-mediated gene expression in hepatocytes [<xref ref-type="bibr" rid="B8">8</xref>]. Nuclear receptor signaling pathways are in hypo-functioning status in an aged person's peripheral blood mononuclear cells [<xref ref-type="bibr" rid="B9">9</xref>]. The incidence of liver cancer is much higher in males than in females, and increases with aging. Based on these observations, we hypothesize that aberrant hepatocyte RXR&#x003b1; signaling might have complex repercussions on cell biological activities and contribute to the risk of liver carcinogenesis in an age and gender dependent manner.</p><p>To study the impact of hepatoctye RXR&#x003b1; deficiency on cancer-related gene expression in each gender, we have performed microarray analyses using livers derived from 6 and 24 month old male and female wild type and hepatocyte RXR&#x003b1;-deficient mice. It is generally recognized that 6 month old mice are mature and 24 month old mice are aged [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. We used Ingenuity Pathway software to identify cancer-related genes. Generally, these genes can be classified into five categories that are associated with carcinogenesis: 1) apoptosis; 2) stress response; 3) cell migration; 4) cell cycle/growth regulation; and 5) immune response. Our data demonstrated that in 6 month old mice, hepatocyte RXR&#x003b1; deficiency resulted in more changes (both in number and fold) of gene expression profiles in male than in female mice; in contrast, in aged mice (24 month old), the pattern was reversed with females showing more changes in genetic expression profiles than their male counterparts. Our data provide a database for identification of candidate genes that might account for gender-, age-, and retinoid signaling-associated liver cancer development.</p></sec><sec><title>Results and discussion</title><p>In 6 month old hepatocyte RXR&#x003b1; deficient mice, 195 genes found in male mice livers had altered expression patterns while 60 genes had changed expression patterns in female mouse livers. In contrast to the matured mice, in aged mice the number of genes that had altered expression patterns due to hepatocyte RXR&#x003b1; deficiency was higher in female (149) than in male (82) mouse livers (table <xref ref-type="table" rid="T1">1</xref>). Our data suggest that hepatocyte RXR&#x003b1; deficiency has a greater impact on males than females in young mice. When mice are aged, the impact is greater in female than in male mice.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Numbers of cancer related genes with altered mRNA levels.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Comparison</td><td align="center" colspan="2">6 month old mice (KO vs. WT)</td><td align="center" colspan="2">24 month old mice (KO vs. WT)</td></tr></thead><tbody><tr><td align="left">Gender</td><td align="center">male</td><td align="center">female</td><td align="center">male</td><td align="center">female</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">apoptosis</td><td align="center">11</td><td align="center">6</td><td align="center">10</td><td align="center">5</td></tr><tr><td align="left">metastasis</td><td align="center">22</td><td align="center">6</td><td align="center">9</td><td align="center">8</td></tr><tr><td align="left">stress inducible</td><td align="center">8</td><td align="center">2</td><td align="center">4</td><td align="center">2</td></tr><tr><td align="left">cell growth</td><td align="center">39</td><td align="center">11</td><td align="center">9</td><td align="center">22</td></tr><tr><td align="left">immune response</td><td align="center">15</td><td align="center">4</td><td align="center">10</td><td align="center">24</td></tr><tr><td align="left">unclassified</td><td align="center">100</td><td align="center">29</td><td align="center">42</td><td align="center">61</td></tr><tr><td align="left">total</td><td align="center">195</td><td align="center">60</td><td align="center">82</td><td align="center">149</td></tr></tbody></table></table-wrap><p>To validate the microarray results, we selected 10 genes to quantify mRNA levels by qRT-PCR. All qRT-PCR analyses were performed on the same samples used for the microarray experiments. Table <xref ref-type="table" rid="T2">2</xref> summarized the fold change in mRNA levels detected by qRT-PCR and microarray experiments. Both methods detected similar trends of expression (up or down regulation) although the fold changes may not be the same. There were only a few exceptions i.e. FKBP5 and USP2. The difference in fold change may reflect the sensitivity difference between the two methods. Generally, the results from both methods were consistent.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Validation the changes of mRNA levels in selected genes.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Comparison</td><td align="center" colspan="2">6 month old mice<break/>KO vs. WT</td><td align="center" colspan="2">24 month old mice<break/>KO vs. WT</td><td align="center">Methods</td></tr></thead><tbody><tr><td align="center">Gender</td><td align="center">male</td><td align="center">female</td><td align="center">male</td><td align="center">female</td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">FKBP5</td><td align="center">4.26</td><td align="center">2.63</td><td align="center">2.81</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">3.26</td><td align="center">2.23</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">USP2</td><td align="center">3.46</td><td align="center">2.17</td><td align="center">3.97</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">3.14</td><td align="center">2.2</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">Caspase 8</td><td align="center">-2.04</td><td align="center">(-)</td><td align="center">-2.31</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-1.98</td><td align="center">(-)</td><td align="center">-3.08</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">THBS1</td><td align="center">-7.11</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-22.21</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">SERPINE1</td><td align="center">-23.48</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-11.76</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">FOS</td><td align="center">-5.74</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-9.94</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">ATF3</td><td align="center">-33.85</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-24.32</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">DNAJB1</td><td align="center">-11.30</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-6.10</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">EGR1</td><td align="center">-15.88</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-9.33</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr><tr><td align="center">BTG2</td><td align="center">-5.26</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">micro-array</td></tr><tr><td></td><td align="center">-9.34</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">(-)</td><td align="center">qRT-PCR</td></tr></tbody></table><table-wrap-foot><p>(-): No significant change on mRNA expression level.</p></table-wrap-foot></table-wrap><p>Many biological processes can be compromised during carcinogenesis. These processes include resistance to apoptosis, unlimited replication potential, self-sufficient growth signal, insensitivity to negative regulators, sustained angiogenesis, and impaired tissue remodeling, all which influence cancer cells to metastasize [<xref ref-type="bibr" rid="B12">12</xref>]. In addition, cell-host interactions such as immune response and stress response pathways have been demonstrated to play important roles in carcinogenesis [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. To reflect these processes, we classified the cancer-related genes, which changed their expression level due to hepatocyte RXR&#x003b1; deficiency, into the five categories: apoptosis, migration, cell growth regulation, stress induction, and immune response.</p><sec><title>Apoptosis-related genes</title><p>In the group of apoptosis-related genes, two general trends were noted in table <xref ref-type="table" rid="T3">3</xref>. (1) The number of genes with varied mRNA levels was always higher in male mutant mice than in female mutant mice. In 6 month old mice, 11 apoptosis-associated genes had altered mRNA levels in male mutant mice while in females; only 6 apoptosis genes had changed expression levels. In 24 month old mice, 10 apoptosis-associated genes had significant changes in mRNA levels in male mutant mice; while in females, the number decreased to 5. (2) Most anti-apoptosis genes had increased mRNA levels; on the contrary, most pro-apoptosis genes had decreased expression levels in due to RXR&#x003b1; deficiency. In male mice, all 4 anti-apoptosis genes in 6 month old mice and 4 out of 5 anti-apoptosis genes in 24 month old mice had increased mRNA levels. On the other hand, 4 out of 7 and 1 out of 1 pro-apoptosis genes decreased in mRNA expression level, respectively, in 6 and 24 month old male mice. The same trend was also found in female mutant mice. A combination effect of up-regulated anti-apoptosis genes and down-regulated pro-apoptosis genes indicated that RXR&#x003b1;-deficient hepatocytes have a more resistant capacity to apoptosis and that hepatocyte RXR&#x003b1; deficiency might have a pro-survival effect.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Fold changes of the mRNA levels of the apoptosis-related genes in male and female hepatocyte RXR&#x003b1;-deficient mouse livers.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3">6 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">6 month female mice (KO <italic>vs</italic>. WT)</td></tr></thead><tbody><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">FKBP5</td><td align="center">4.26</td><td align="center">anti-apoptosis</td><td align="center">FKBP5</td><td align="center">2.63</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">USP2</td><td align="center">3.46</td><td align="center">anti-apoptosis</td><td align="center">USP2</td><td align="center">2.17</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">CFLAR</td><td align="center">2.56</td><td align="center">anti-apoptosis</td><td align="center">BCL6</td><td align="center">2.14</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">BGN</td><td align="center">2.4</td><td align="center">anti-apoptosis</td><td align="center">SERPINA3K</td><td align="center">2.06</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">BIK</td><td align="center">4.41</td><td align="center">pro-apoptosis</td><td align="center">BGN</td><td align="center">-2.12</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">ACVR2B</td><td align="center">3.55</td><td align="center">pro-apoptosis</td><td align="center">ANP32A</td><td align="center">-2.01</td><td align="center">pro-apoptosis</td></tr><tr><td align="center">BNIP2</td><td align="center">2.09</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">CASP8</td><td align="center">-2.04</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">EMP2</td><td align="center">-2.7</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">DUSP6</td><td align="center">-4.26</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">BCL2L11</td><td align="center">-5.61</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center" colspan="3">24 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">24 month female mice (KO <italic>vs</italic>. WT)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">Function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">USP2</td><td align="center">3.97</td><td align="center">anti-apoptosis</td><td align="center">IER3</td><td align="center">2.23</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">FKBP5</td><td align="center">2.81</td><td align="center">anti-apoptosis</td><td align="center">BCL6</td><td align="center">2.08</td><td align="center">anti-apoptosis</td></tr><tr><td align="center">IER3</td><td align="center">2.8</td><td align="center">anti-apoptosis</td><td align="center">BIK</td><td align="center">2.22</td><td align="center">pro-apoptosis</td></tr><tr><td align="center">DUSP1</td><td align="center">2.3</td><td align="center">anti-apoptosis</td><td align="center">WNK1</td><td align="center">-2.35</td><td align="center">pro-apoptosis</td></tr><tr><td align="center">BIRC4</td><td align="center">-3.19</td><td align="center">anti-apoptosis</td><td align="center">DIABLO</td><td align="center">-2.87</td><td align="center">pro-apoptosis</td></tr><tr><td align="center">CASP1</td><td align="center">2.83</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">UBE1L</td><td align="center">2.36</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">ZBTB16</td><td align="center">2.19</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">SOX9</td><td align="center">-2.09</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr><tr><td align="center">CASP8</td><td align="center">-2.27</td><td align="center">pro-apoptosis</td><td></td><td></td><td></td></tr></tbody></table></table-wrap><p>Among the anti-apoptosis genes, FKBP5 (FK506 binding protein 5) mRNA levels were increased by 4.26- and 2.63-fold in 6 month old male and female mice, respectively, due to hepatocyte RXR&#x003b1;-deficiency, and the data were confirmed by real-time PCR. FKBP5 is a co-chaperone molecular which interacts with HSP90 (Heat Shock Protein 90) [<xref ref-type="bibr" rid="B15">15</xref>]. Its roles include up-regulating the NF-&#x003ba;B pathway and stimulating Bcl2 transcription. FKBP5 could be up-regulated by androgen, glucocorticoids, and progestin hormones [<xref ref-type="bibr" rid="B15">15</xref>]. There is no evidence showing that FKBP5 is directly associated with RXR&#x003b1;-mediated signaling. However, RXR&#x003b1; could negatively modulate androgen signaling through binding androgen receptors directly [<xref ref-type="bibr" rid="B16">16</xref>]. It is possible that in RXR&#x003b1;-deficient hepatocytes, the androgen-mediated signaling could have enhanced activation levels compared with wild-type mice thus leading to higher expression levels of FKBP5.</p><p>Another anti-apoptosis gene, USP2 (Ubiquitin Specific Peptidase 2), also showed increased mRNA levels by 3.46- and 2.17-fold in 6 month old hepatocyte RXR&#x003b1; deficient male and female mice, respectively. USP2 is a de-ubiquitinase protein and increases Mdm2 (mouse double minute 2) [<xref ref-type="bibr" rid="B17">17</xref>] and FAS (fatty acid synthase) protein stability [<xref ref-type="bibr" rid="B18">18</xref>]. Since Mdm2 is responsible for p53 degradation, USP2 could negatively regulate the p53 pathway activity through up-regulation of Mdm2. In prostate cancer cells, USP2 interacts with and stabilizes FAS, which is often over-expressed in biologically aggressive human tumors. Functional inactivation of USP2 results in decreased FAS protein and enhanced apoptosis in prostate cancer [<xref ref-type="bibr" rid="B18">18</xref>]. As with FKBP5, USP2 is also up-regulated by androgen. The similarly elevated expression patterns for FKBP5 and USP2 genes suggest that they are likely regulated by the same mechanism, possibly up-regulation of androgen signaling activity due to RXR&#x003b1; deficiency. In addition, the qRT-PCR results showed that in both genders, the levels of FKBP5 and USP2 mRNA were not increased in 24 month old mutant mice probably due to decreased androgen level in aged mice.</p><p>We previously showed that hepatocyte RXR&#x003b1;-deficient mice have increased serum cholesterol and triglyceride levels [<xref ref-type="bibr" rid="B5">5</xref>], indicating an altered fatty acid metabolism pathway. Our results implied elevated serum triglyceride and cholesterol levels might in part be due to increased activity of FAS because of up-regulation of USP2. Collectively, the changed trends in apoptosis related genes implied that RXR&#x003b1;-deficient hepatocytes have an increased resistance to apoptosis.</p></sec><sec><title>Migration-related genes</title><p>Genes in this group play important roles in cell migration and angiogenesis and are associated with metastasis, a key feature of malignant cancer cells. Generally, the trends observed in this group were different depending upon age and gender (table <xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Fold changes of the mRNA levels of the metastasis-related genes in male and female hepatocyte RXR&#x003b1;-deficient mouse livers.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3">6 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">6 month female mice (KO <italic>vs</italic>. WT)</td></tr></thead><tbody><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">Function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">ARHGDIB</td><td align="center">-2.05</td><td align="center">anti-metastasis</td><td align="center">BRMS1</td><td align="center">-2.16</td><td align="center">anti-metastasis</td></tr><tr><td align="center">KRT18</td><td align="center">-2.15</td><td align="center">anti-metastasis</td><td align="center">CD36</td><td align="center">-2.88</td><td align="center">anti-metastasis</td></tr><tr><td align="center">CD36</td><td align="center">-2.16</td><td align="center">anti-metastasis</td><td align="center">MYO10</td><td align="center">2.63</td><td align="center">pro-metastasis</td></tr><tr><td align="center">KRT19</td><td align="center">-2.43</td><td align="center">anti-metastasis</td><td align="center">ROCK1</td><td align="center">-2.24</td><td align="center">pro-metastasis</td></tr><tr><td align="center">THBS1</td><td align="center">-7.11</td><td align="center">anti-metastasis</td><td align="center">CTTN</td><td align="center">-2.88</td><td align="center">pro-metastasis</td></tr><tr><td align="center">SERPINE1</td><td align="center">-23.48</td><td align="center">anti-metastasis</td><td align="center">ITGA6</td><td align="center">-3.64</td><td align="center">pro-metastasis</td></tr><tr><td align="center">CAV1</td><td align="center">2.86</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">FN1</td><td align="center">2.67</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">ID2</td><td align="center">2.65</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">DDEF1</td><td align="center">2.52</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">CLCA1</td><td align="center">2.33</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">S100A10</td><td align="center">-2.09</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">ADAM12</td><td align="center">-2.12</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">CNN2</td><td align="center">-2.16</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">PLAUR</td><td align="center">-2.25</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">PLAT</td><td align="center">-2.30</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">NEDD9</td><td align="center">-2.39</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">SPP1</td><td align="center">-2.75</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">CTGF</td><td align="center">-2.90</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">VIM</td><td align="center">-3.25</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">LGALS7</td><td align="center">-3.79</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td align="center">EPHA2</td><td align="center">-4.71</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center" colspan="3">24 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">24 month female mice (KO <italic>vs</italic>. WT)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">Function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">TIMP4</td><td align="center">4.07</td><td align="center">anti-metastasis</td><td align="center">DDR1</td><td align="center">-2.20</td><td align="center">anti-metastasis</td></tr><tr><td align="center">ANK3</td><td align="center">2.07</td><td align="center">anti-metastasis</td><td align="center">TFF3</td><td align="center">11.22</td><td align="center">pro-metastasis</td></tr><tr><td align="center">LGALS3</td><td align="center">2.00</td><td align="center">anti-metastasis</td><td align="center">ADAM15</td><td align="center">3.38</td><td align="center">pro-metastasis</td></tr><tr><td align="center">TFF3</td><td align="center">4.05</td><td align="center">pro-metastasis</td><td align="center">MMP9</td><td align="center">2.49</td><td align="center">pro-metastasis</td></tr><tr><td align="center">CTGF</td><td align="center">2.22</td><td align="center">pro-metastasis</td><td align="center">ITGB1</td><td align="center">2.48</td><td align="center">pro-metastasis</td></tr><tr><td align="center">MT1E</td><td align="center">2.19</td><td align="center">pro-metastasis</td><td align="center">CSF2RB</td><td align="center">2.32</td><td align="center">pro-metastasis</td></tr><tr><td align="center">CAV1</td><td align="center">2.15</td><td align="center">pro-metastasis</td><td align="center">FOXM1</td><td align="center">2.13</td><td align="center">pro-metastasis</td></tr><tr><td align="center">PLAUR</td><td align="center">2.03</td><td align="center">pro-metastasis</td><td align="center">MYO6</td><td align="center">-4.70</td><td align="center">pro-metastasis</td></tr><tr><td align="center">PTP4A3</td><td align="center">-2.55</td><td align="center">pro-metastasis</td><td></td><td></td><td></td></tr></tbody></table></table-wrap><p>In 6 month male RXR&#x003b1;-deficient mice, 22 genes showed significant change in mRNA levels. Among those, 6 out of 6 anti-metastasis genes showed reduction of mRNA levels because of RXR&#x003b1; deficiency. Other genes associated with pro-metastasis showed either up- or down-regulation in mRNA levels due to RXR&#x003b1; deficiency. In female hepatocyte RXR&#x003b1;-deficient mice, only 6 migration-related genes showed significant changes in their mRNA level.</p><p>At 24 month of age, male and female mutant mice showed 9 and 8 genes with alteration in their mRNA levels, respectively. Thus, in aged mice, the difference in the number of genes with deviated mRNA levels is no longer obvious between genders; in contrast, at 6 month of age, the numbers of genes with altered mRNA levels in male and female mutant mice were 22 and 6, respectively. Another striking observation was that many pro-metastasis genes increased their mRNA levels in aged RXR&#x003b1; deficient mice. In contrast, very few anti-metastasis associated genes showed change in mRNA levels in aged mice.</p><p>In the group of anti-metastasis associated genes, the levels of CD36, THBS1 (thrombospondin 1), and SERPINE1 (Serpin Peptidase Inhibitor) mRNA decreased by 2.16-, 7.11-, and 23.48-fold, respectively, in 6 month old male mutant mice. Real time PCR results showed that THBS1 and SERPINE1 were down-regulated in mRNA levels by 22.21-, and 11.76-fold, respectively. THBS1 is the receptor for CD36 and a potent angiogenesis inhibitor. Down-regulation of THBS1 has been suggested to increase tumor growth and metastasis by modulating angiogenesis in a variety of tumor types [<xref ref-type="bibr" rid="B19">19</xref>]. SERPINE1, also named PAI-1 (plasminogen activator inhibitor-1), has been used in gene therapy for inhibition of melanoma metastasis [<xref ref-type="bibr" rid="B20">20</xref>]. There were also some pro-metastasis genes, such as CAV1 (caveolin 1) and FN1 (fibronectin 1), which exhibited increased mRNA levels by 2.86- and 2.67-fold, respectively, in 6 month old male mice. On the contrary, in female hepatocyte RXR&#x003b1;-deficient mice, those genes, except CD36, did not show changes in expression levels. These observed expression patterns indicate that RXR&#x003b1; deficiency had a greater impact on metastasis related gene expression in males than in female mice at an earlier stage of life. It also suggests that hepatocytes in male mutant mice might have more cell movement ability than wild type hepatocytes.</p><p>Our data indicated that RXR&#x003b1;-deficient hepatocytes might have more metastasis ability than normal hepatocytes. Male mutant mice at 6 month of age had 22 genes with changed their mRNA levels. All 8 anti-metastasis genes showed decreased mRNA levels. When mice were 24 month old, the up-regulation of mRNA levels in pro-metastasis related genes became more robust in hepatocyte RXR&#x003b1;-deficient mice. It has been revealed that RXR&#x003b1; ligands could inhibit cell migration through deregulation of matrix metalloproteinase-9 or TIMP-1 production [<xref ref-type="bibr" rid="B21">21</xref>]. Down-regulation of THBS1 and SERPINE1 when retinoid signaling is compromised provide another mechanism by which retinoids might have an anti-metastasis role. Our data also suggest that the impact of RXR&#x003b1; on metastasis is gender and age dependent.</p></sec><sec><title>Stress response-related genes</title><p>Several HSP (Heat Shock Protein) genes decreased their mRNA levels due to RXR&#x003b1; deficiency (table <xref ref-type="table" rid="T5">5</xref>). At 6 month of age, male and female mutant mice had 6 and 2 HSP genes with decreased mRNA levels, respectively. At 24 month of age, two HSP genes, HSPB1 (heat shock 27 kDa protein 1) and HYOU1 (hypoxia up-regulated 1), showed decreased mRNA levels due to RXR&#x003b1; deficiency.</p><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Fold changes of the mRNA levels of the stress-inducible genes in male and female hepatocyte RXR&#x003b1;-deficient mouse livers.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3">6 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">6 month female mice (KO <italic>vs</italic>. WT)</td></tr></thead><tbody><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">GADD45G</td><td align="center">3.89</td><td align="center">stress inducible</td><td align="center">HSPA8</td><td align="center">-2.50</td><td align="center">stress inducible</td></tr><tr><td align="center">DDIT4</td><td align="center">2.30</td><td align="center">stress inducible</td><td align="center">HSPB1</td><td align="center">-4.66</td><td align="center">stress inducible</td></tr><tr><td align="center">DNAJB4</td><td align="center">-2.39</td><td align="center">stress inducible</td><td></td><td></td><td></td></tr><tr><td align="center">HSPA1B</td><td align="center">-3.42</td><td align="center">stress inducible</td><td></td><td></td><td></td></tr><tr><td align="center">HSPB1</td><td align="center">-3.86</td><td align="center">stress inducible</td><td></td><td></td><td></td></tr><tr><td align="center">HSPA1A</td><td align="center">-10.29</td><td align="center">stress inducible</td><td></td><td></td><td></td></tr><tr><td align="center">DNAJB1</td><td align="center">-11.30</td><td align="center">stress inducible</td><td></td><td></td><td></td></tr><tr><td align="center">ATF3</td><td align="center">-33.85</td><td align="center">stress inducible</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center" colspan="3">24 month male (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">24 month female (KO <italic>vs</italic>. WT)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">GADD45G</td><td align="center">2.86</td><td align="center">stress inducible</td><td align="center">HIF1A</td><td align="center">2.50</td><td align="center">stress inducible</td></tr><tr><td align="center">DDIT4</td><td align="center">2.18</td><td align="center">stress inducible</td><td align="center">HIPK2</td><td align="center">-2.22</td><td align="center">stress inducible</td></tr><tr><td align="center">HSPB1</td><td align="center">-2.59</td><td align="center">stress inducible</td><td align="center">HSPB1</td><td align="center">-2.62</td><td align="center">stress inducible</td></tr><tr><td align="center">HYOU1</td><td align="center">-2.75</td><td align="center">stress inducible</td><td align="center">HYOU1</td><td align="center">-3.54</td><td align="center">stress inducible</td></tr></tbody></table></table-wrap><p>The HSP gene family is highly conserved in structure from C. elegans to humans. HSP genes constitute the cellular protection mechanism and can be induced by various physical, chemical, and biological factors. In 6 month old RXR&#x003b1;-deficient male mice, DNAJB1 (Dnaj homologue, subfamily B, member 1), HSPB1, HSPA1A (Heat Shock 70 KDa Protein 1A), and HSPA1B (Heat Shock 70 KDa Protein 1B) had reduced mRNA levels by 11.30-, 10.29-, 3.86-, and 3.42-fold, respectively. This coordinated down-regulation of the HSP family genes indicated that these genes were regulated by common mechanisms. In 6 month old hepatocyte RXR&#x003b1;-deficient female mice, only 2 genes (HSPA8 and HSPB1) had reduced mRNA levels of 2.50- and 4.66-fold, respectively. Thus, hepatocyte RXR&#x003b1; deficiency has a greater impact on HSP gene expression in male than in female mice. In aged mice, there was no gender difference in the expression pattern of the HSP family genes related to RXR&#x003b1; deficiency. HSPB1 and HYOU1 both exhibited decreased mRNA levels in male and female aged mutant mice to a similar extent. HSPB1 mRNA levels were consistently decreased in both male and female mutant mice of both age groups.</p><p>Some small HSP genes expression levels such as HSP27 can be up-regulated by RXR/RAR heterodimer in lens [<xref ref-type="bibr" rid="B22">22</xref>]; furthermore, RXR ligand 9-cis RA (retinoid acid) increases the HSP gene expression in Jurkat cells [<xref ref-type="bibr" rid="B23">23</xref>]. Rocchi, P., et al. suggested that the expression of HSPB1 could be up-regulated by androgen ablation [<xref ref-type="bibr" rid="B24">24</xref>]. Another report revealed that exogenous androgen treatment could delay stress response by decreasing the expression of HSP70 [<xref ref-type="bibr" rid="B25">25</xref>]. Down-regulation of these HSP genes implied that RXR&#x003b1;-deficient hepatocytes had a reduced protective ability and might be more susceptible to injury resulted from external stimuli compared with wild type hepatocytes. It is possible that there was increased androgen signaling activity due to RXR&#x003b1; deficiency because RXR&#x003b1; is a negative regulator for the androgen pathway, leading to inhibition of HSP family mRNA expression. Another phenomenon that we observed is that the number of HSP family genes which showed alteration in mRNA levels is higher in male than in female when mice are 6 month old. However, this gap decreased when mice were aged. Since androgen levels are higher in male than in female and decrease during aging, the physiological changes of androgen levels may account for this gender- and age-dependent gene expression pattern. It has been shown that RXR&#x003b1;-deficient hepatocytes have a shortened lifespan [<xref ref-type="bibr" rid="B6">6</xref>]. Our data implied down-regulation of HSP genes expression in RXR&#x003b1;-deficient hepatocytes might result in decreased cell protection ability and consequently render the cells prone to death.</p></sec><sec><title>Cell growth regulation-related genes</title><p>Retinoids could arrest cell cycle progression and induce apoptosis in many types of cancer cells through activation of RXRs. RXR&#x003b1; signaling plays critical roles in cell growth and differentiation. In RXR&#x003b1; hepatocyte-deficient mice, many genes associated with cell growth had changes in their mRNA levels. Again, this difference in gene expression pattern is gender and age dependent (table <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap position="float" id="T6"><label>Table 6</label><caption><p>Fold changes of the mRNA levels of the cell growth-related genes in male and female hepatocyte RXR&#x003b1;-deficient mouse livers.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3">6 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">6 month female mice (KO <italic>vs</italic>. WT)</td></tr></thead><tbody><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">LCN2</td><td align="center">6.37</td><td align="center">oncogene</td><td align="center">LCN2</td><td align="center">4.57</td><td align="center">oncogene</td></tr><tr><td align="center">PIM1</td><td align="center">4.10</td><td align="center">oncogene</td><td align="center">GFRA1</td><td align="center">2.15</td><td align="center">oncogene</td></tr><tr><td align="center">MAFB</td><td align="center">4.07</td><td align="center">oncogene</td><td align="center">PTTG1</td><td align="center">-4</td><td align="center">oncogene</td></tr><tr><td align="center">ERBB3</td><td align="center">2.05</td><td align="center">oncogene</td><td align="center">PROM1</td><td align="center">-5.61</td><td align="center">oncogene</td></tr><tr><td align="center">REL</td><td align="center">-2.34</td><td align="center">oncogene</td><td align="center">PLAGL1</td><td align="center">-2.09</td><td align="center">suppressor</td></tr><tr><td align="center">MDM2)</td><td align="center">-2.47</td><td align="center">oncogene</td><td align="center">KLF6</td><td align="center">-2.19</td><td align="center">suppressor</td></tr><tr><td align="center">JUN</td><td align="center">-2.87</td><td align="center">oncogene</td><td align="center">WWOX</td><td align="center">-2.2</td><td align="center">suppressor</td></tr><tr><td align="center">RHOB</td><td align="center">-2.93</td><td align="center">oncogene</td><td align="center">CAPG</td><td align="center">-2.23</td><td align="center">suppressor</td></tr><tr><td align="center">PTTG1</td><td align="center">-2.95</td><td align="center">oncogene</td><td align="center">KLF4</td><td align="center">-2.32</td><td align="center">suppressor</td></tr><tr><td align="center">RHOC</td><td align="center">-3.06</td><td align="center">oncogene</td><td align="center">GJA1</td><td align="center">-2.91</td><td align="center">suppressor</td></tr><tr><td align="center">ROS1</td><td align="center">-3.14</td><td align="center">oncogene</td><td align="center">GSN</td><td align="center">-3.18</td><td align="center">suppressor</td></tr><tr><td align="center">SERTAD1</td><td align="center">-3.7</td><td align="center">oncogene</td><td align="center">PEG3</td><td align="center">-5.96</td><td align="center">suppressor</td></tr><tr><td align="center">PML</td><td align="center">-3.9</td><td align="center">oncogene</td><td align="center">TPM1</td><td align="center">-11.95</td><td align="center">suppressor</td></tr><tr><td align="center">ETS2</td><td align="center">-4.97</td><td align="center">oncogene</td><td></td><td></td><td></td></tr><tr><td align="center">FOS</td><td align="center">-5.74</td><td align="center">oncogene</td><td></td><td></td><td></td></tr><tr><td align="center">MYC</td><td align="center">-7.7</td><td align="center">oncogene</td><td></td><td></td><td></td></tr><tr><td align="center">SOCS3</td><td align="center">3.85</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">MAD1L1</td><td align="center">3.73</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">TCF21</td><td align="center">2.82</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">CEBPD</td><td align="center">2.77</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">SSBP2</td><td align="center">2.27</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">NDRG1</td><td align="center">2.19</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">HMGN1</td><td align="center">2.1</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">SLC22A18</td><td align="center">2.08</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">AIM1</td><td align="center">2.05</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">KSR1</td><td align="center">2.04</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">CDKN1A</td><td align="center">-2.32</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">MBL2</td><td align="center">-2.34</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">GSN</td><td align="center">-2.42</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">TPM1</td><td align="center">-2.46</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">PSRC1</td><td align="center">-2.78</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">GPX3</td><td align="center">-2.8</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">PERP</td><td align="center">-3.42</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">MSX1</td><td align="center">-3.5</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">MBD1</td><td align="center">-4.15</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">BTG2</td><td align="center">-5.26</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">KLF6</td><td align="center">-5.67</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">EGR2</td><td align="center">-6.03</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td align="center">EGR1</td><td align="center">-15.88</td><td align="center">suppressor</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="center" colspan="3">24 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">24 month female mice (KO <italic>vs</italic>. WT)</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">JUN</td><td align="center">2.29</td><td align="center">oncogene</td><td align="center">LIMK1</td><td align="center">4.9</td><td align="center">oncogene</td></tr><tr><td align="center">PTTG1</td><td align="center">2.25</td><td align="center">oncogene</td><td align="center">ROS1</td><td align="center">4.51</td><td align="center">oncogene</td></tr><tr><td align="center">PLK3</td><td align="center">3.91</td><td align="center">suppressor</td><td align="center">CCND1</td><td align="center">4.44</td><td align="center">oncogene</td></tr><tr><td align="center">BLNK</td><td align="center">2.13</td><td align="center">suppressor</td><td align="center">APC</td><td align="center">2.87</td><td align="center">oncogene</td></tr><tr><td align="center">GPX3</td><td align="center">2.11</td><td align="center">suppressor</td><td align="center">MAFB</td><td align="center">2.57</td><td align="center">oncogene</td></tr><tr><td align="center">BEXL1</td><td align="center">2.08</td><td align="center">suppressor</td><td align="center">MYBL2</td><td align="center">2.54</td><td align="center">oncogene</td></tr><tr><td align="center">WWOX</td><td align="center">-2.00</td><td align="center">suppressor</td><td align="center">SH2B2</td><td align="center">2.25</td><td align="center">oncogene</td></tr><tr><td align="center">PEG3</td><td align="center">-2.2</td><td align="center">suppressor</td><td align="center">PDGFB</td><td align="center">2.23</td><td align="center">oncogene</td></tr><tr><td align="center">WISP1</td><td align="center">-3.48</td><td align="center">suppressor</td><td align="center">E2F3</td><td align="center">2.08</td><td align="center">oncogene</td></tr><tr><td align="center">PERP</td><td align="center">-4.03</td><td align="center">suppressor</td><td align="center">FLT4</td><td align="center">2.02</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">MYCL1</td><td align="center">-2.08</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">GPC1</td><td align="center">-2.09</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">CDK5</td><td align="center">-2.11</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">DCT</td><td align="center">-2.3</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">SH3RF1</td><td align="center">-2.35</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">NKX2-5</td><td align="center">-2.42</td><td align="center">oncogene</td></tr><tr><td></td><td></td><td></td><td align="center">BANP</td><td align="center">3.97</td><td align="center">suppressor</td></tr><tr><td></td><td></td><td></td><td align="center">PEG3</td><td align="center">2.91</td><td align="center">suppressor</td></tr><tr><td></td><td></td><td></td><td align="center">IFI16</td><td align="center">2.63</td><td align="center">suppressor</td></tr><tr><td></td><td></td><td></td><td align="center">BLNK</td><td align="center">-2.55</td><td align="center">suppressor</td></tr><tr><td></td><td></td><td></td><td align="center">DKK3</td><td align="center">-4.13</td><td align="center">suppressor</td></tr><tr><td></td><td></td><td></td><td align="center">GPR65</td><td align="center">-6.82</td><td align="center">suppressor</td></tr></tbody></table></table-wrap><p>More genes altered expression patterns in male mutant mice compared with female mutant mice at 6 month of age (both in numbers and fold). For example, Jun, Fos, and Myc mRNA levels decreased by 2.87-, 5.74-, and 7.76-fold, respectively, in male mutant mice; on the other hand, tumor suppressor genes such as KLF6 (Kruppel-like factor 6), EGR2, and EGR1 (early growth response 2 and 1) were down-regulated by 5.67-, 6.03-, and 15.88-fold, respectively. KLF6 inhibits cell proliferation through up-regulation of p21 expression in liver cells [<xref ref-type="bibr" rid="B26">26</xref>]. EGR1 and 2, early transcription factors, increase apoptosis in tumor cells. The down-regulation of oncogenes indicated that in RXR&#x003b1;-deficient hepatocytes, the cell growth activity was compromised, providing another reason for the observed shortened cell lifespan due to RXR&#x003b1; deficiency. The same trend observed in tumor suppressor genes suggested that negative regulation of cell cycle was also impaired. For example, p21 is up-regulated by activation of RXR/RAR dimer in HepG2 cells [<xref ref-type="bibr" rid="B27">27</xref>]. Consistently, our data showed the decrease of p21 mRNA levels by 2.32 folds in 6 month old male mutant mice. BTG2 (B-cell translocation gene 2), a downstream effector of the p53 pathway [<xref ref-type="bibr" rid="B28">28</xref>], also had a 5.26 fold reduction. Several genes belonging to the p53 pathway had altered mRNA levels and lead to compromised p53 pathway activity. The impairment of the p53 pathway and other negative regulators implied that due to RXR&#x003b1; deficiency hepatocytes would surpass the cell cycle barrier more easily and be transformed into malignant cells. In female mutant mice, the mRNA levels of the above mentioned genes were not changed. One obvious trend the data points to is that all negative regulator genes for cell cycle transition decreased their mRNA levels in female mutant mice. It also implies cell cycle checkpoint machinery is impaired in female mutant mice.</p><p>Contrary to 6 month old female mutant mice, 24 month old female mutant mice had more genes with modified mRNA levels than did the male mutant mice of the same age group (22 vs. 10). In addition, no obvious trends in gene expression patterns were noted. Oncogenes and tumor suppressor genes were up or down regulated randomly.</p><p>The impact of RXR-mediated pathways on cell growth is very complex. It can be tissue- or cell type-specific. The activation of RXR/CAR, RXR/PXR, and RXR/PPAR&#x003b1; pathways could induce hepatomegaly [<xref ref-type="bibr" rid="B29">29</xref>-<xref ref-type="bibr" rid="B31">31</xref>]. On the contrary, RXR/RAR or RXR/VDR pathways inhibit tumor cell growth [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. It is likely that the complexity of changes seen in gene expression profiles reflect the net results of combined proliferative and anti-proliferative effects due to hepatocyte RXR&#x003b1; deficiency.</p><p>Our data implied that in matured livers, RXR&#x003b1; deficiency has more impact on cell growth-related gene expression levels in males than in females; but in aged liver, female mice have more changes in cell growth-related gene expression patterns than do male mice.</p></sec><sec><title>Immune response-related genes</title><p>Immune response-related genes also had significant changes in mRNA level due to RXR&#x003b1; deficiency (table <xref ref-type="table" rid="T7">7</xref>). At 6 month of age, male and female mutant mice had 15 and 4 genes with modified mRNA levels, respectively; however, at 24 month of age, there were 10 and 24 genes with change expression levels in male and female mice, respectively. In aged mice, the number of genes with altered mRNA levels increased significantly in female mutant mice. Another striking change in aged mice was that most of the immune response-related genes (8 out of 10 in males and 18 out of 24 in females) increased in mRNA levels. Such expression trends were not found in 6 month old mice, implying increased inflammation status might occur in both genders at old age due to RXR&#x003b1; deficiency.</p><table-wrap position="float" id="T7"><label>Table 7</label><caption><p>Fold changes of the mRNA levels of the immune response genes in male and female hepatocyte RXR&#x003b1;-deficient mouse livers.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3">6 month male mice (KO <italic>vs</italic>. WT)</td><td align="center" colspan="3">6 month female mice (KO <italic>vs</italic>. WT)</td></tr></thead><tbody><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="center">DSCR1</td><td align="center">-5.50</td><td align="center">immune response</td><td align="center">CD9</td><td align="center">-2.2</td><td align="center">immune response</td></tr><tr><td align="center">CXCL10</td><td align="center">-4.47</td><td align="center">immune response</td><td align="center">CD24</td><td align="center">-4.2</td><td align="center">immune response</td></tr><tr><td align="center">IKBKB</td><td align="center">-3.31</td><td align="center">immune response</td><td align="center">HLA-G</td><td align="center">-2.38</td><td align="center">immune response</td></tr><tr><td align="center">LIFR</td><td align="center">-3.25</td><td align="center">immune response</td><td align="center">FSTL1</td><td align="center">-2.14</td><td align="center">immune response</td></tr><tr><td align="center">IGHG1</td><td align="center">-2.53</td><td align="center">immune response</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td align="center">S100A9</td><td align="center">-2.39</td><td align="center">immune response</td><td align="center" colspan="3">24 month female mice (KO <italic>vs</italic>. WT)</td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td align="center">IGHM</td><td align="center">-2.17</td><td align="center">immune response</td><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td align="center">MME</td><td align="center">-2.17</td><td align="center">immune response</td><td align="center">B2M</td><td align="center">-2.47</td><td align="center">immune response</td></tr><tr><td align="center">FCGR2B</td><td align="center">-2.14</td><td align="center">immune response</td><td align="center">IL7</td><td align="center">-2.38</td><td align="center">immune response</td></tr><tr><td align="center">CXXC5</td><td align="center">2.01</td><td align="center">immune response</td><td align="center">IL17RD</td><td align="center">-2.28</td><td align="center">immune response</td></tr><tr><td align="center">CCL19</td><td align="center">2.04</td><td align="center">immune response</td><td align="center">LIFR</td><td align="center">-2.07</td><td align="center">immune response</td></tr><tr><td align="center">TAX1BP1</td><td align="center">2.13</td><td align="center">immune response</td><td align="center">HLA-G</td><td align="center">-2.03</td><td align="center">immune response</td></tr><tr><td align="center">SAA4</td><td align="center">2.18</td><td align="center">immune response</td><td align="center">NFATC2</td><td align="center">-2.03</td><td align="center">immune response</td></tr><tr><td align="center">CXCL2</td><td align="center">3.39</td><td align="center">immune response</td><td align="center">CD14</td><td align="center">2.02</td><td align="center">immune response</td></tr><tr><td align="center">HLA-G</td><td align="center">3.76</td><td align="center">immune response</td><td align="center">CD48</td><td align="center">2.02</td><td align="center">immune response</td></tr><tr><td></td><td></td><td></td><td align="center">FCER1G</td><td align="center">2.05</td><td align="center">immune response</td></tr><tr><td></td><td></td><td></td><td align="center">HLA-E</td><td align="center">2.05</td><td align="center">immune response</td></tr><tr><td></td><td></td><td></td><td align="center">NFATC4</td><td align="center">2.06</td><td align="center">immune response</td></tr><tr><td></td><td></td><td></td><td align="center">IL1RN</td><td align="center">2.14</td><td align="center">immune response</td></tr><tr><td colspan="3"><hr></hr></td><td></td><td></td><td></td></tr><tr><td align="center" colspan="3">24 month male mice (KO <italic>vs</italic>. WT)</td><td align="center">IGHM</td><td align="center">2.23</td><td align="center">immune response</td></tr><tr><td colspan="3"><hr></hr></td><td></td><td></td><td></td></tr><tr><td align="center">Name</td><td align="center">Fold Change</td><td align="center">function</td><td align="center">CD24</td><td align="center">2.38</td><td align="center">immune response</td></tr><tr><td colspan="3"><hr></hr></td><td></td><td></td><td></td></tr><tr><td align="center">IL13RA1</td><td align="center">-2.57</td><td align="center">immune response</td><td align="center">S100A9</td><td align="center">2.4</td><td align="center">immune response</td></tr><tr><td align="center">HLA-G</td><td align="center">-2.33</td><td align="center">immune response</td><td align="center">NFE2</td><td align="center">2.42</td><td align="center">immune response</td></tr><tr><td align="center">DSCR1</td><td align="center">2.01</td><td align="center">immune response</td><td align="center">IL12RB1</td><td align="center">2.46</td><td align="center">immune response</td></tr><tr><td align="center">CCL7</td><td align="center">2.03</td><td align="center">immune response</td><td align="center">LIF</td><td align="center">2.6</td><td align="center">immune response</td></tr><tr><td align="center">NTRK3</td><td align="center">2.23</td><td align="center">immune response</td><td align="center">IL1A</td><td align="center">2.76</td><td align="center">immune response</td></tr><tr><td align="center">NTRK2</td><td align="center">2.29</td><td align="center">immune response</td><td align="center">IL16</td><td align="center">2.83</td><td align="center">immune response</td></tr><tr><td align="center">CXCL3</td><td align="center">2.47</td><td align="center">immune response</td><td align="center">SLPI</td><td align="center">2.97</td><td align="center">immune response</td></tr><tr><td align="center">CLEC2D</td><td align="center">4.41</td><td align="center">immune response</td><td align="center">CD55</td><td align="center">3</td><td align="center">immune response</td></tr><tr><td align="center">CXCL10</td><td align="center">5.92</td><td align="center">immune response</td><td align="center">MARCO</td><td align="center">3.24</td><td align="center">immune response</td></tr><tr><td align="center">IGH-1A</td><td align="center">8.93</td><td align="center">immune response</td><td align="center">MEF2C</td><td align="center">5.03</td><td align="center">immune response</td></tr></tbody></table></table-wrap><p>The RXR/PPAR dimer attenuates the inflammation response in colon [<xref ref-type="bibr" rid="B32">32</xref>]. RXR and PPAR agonists decrease TNF&#x003b1; (tumor necrosis factor &#x003b1;) and IL-1&#x003b2; (interleukin 1&#x003b2;) mRNA levels. In liver tissue, the acute response to external stimulus was associated with a down-regulation of RXR&#x003b1; expression [<xref ref-type="bibr" rid="B33">33</xref>]. Lipopolysaccharide (LPS) induces a rapid, dose-dependent decrease in RXR&#x003b1;, &#x003b2;, and &#x003b3; proteins in hamster liver [<xref ref-type="bibr" rid="B33">33</xref>]. Alcohol induced pro-inflammation gene expression (TNF&#x003b1;, IL6, and IL1&#x003b2;) is enhanced due to hepatocyte RXR&#x003b1; deficiency [<xref ref-type="bibr" rid="B34">34</xref>]. These observations implied an inverse correlation between inflammation and RXR&#x003b1; signaling. These findings indicate that RXR&#x003b1; deficiency increases inflammation response to stimulus, which might be due to deregulation of a panel of immune-related genes. Furthermore, the impact of RXR&#x003b1; deficiency on immune response genes was more obvious in aged than in young mice.</p></sec><sec><title>The impact of hepatocyte RXR&#x003b1;-deficiency on the expression of gender-dependent genes</title><p>The expression of many hepatic genes are gender dependent [<xref ref-type="bibr" rid="B35">35</xref>]. However, the findings might vary depending upon the age and strain of mice studied. The susceptibility of night blindness and xerophthalmia, the most common symptoms of vitamin A deficiency, are also gender dependent; the incidence is higher in males than females [<xref ref-type="bibr" rid="B36">36</xref>]. Thus, we studied the impact of RXR&#x003b1; deficiency on the expression of hepatic cancer-related genes that have a gender-dependent expression pattern. Our data showed that the numbers of gender-dependent genes in 6 month old wild type and hepatocyte RXR&#x003b1;-deficient mice are 329 and 200, respectively. When the mice were aged, the number of gender-dependent genes in wild type mice dropped significantly (127), but not so much in mutant mice (167) suggesting aging narrowed the gender gap more in wild type mice than in the mutant mice (table <xref ref-type="table" rid="T8">8</xref>). There were common gender-dependent genes in both wild type and hepatocyte RXR&#x003b1;-deficient mice. The names of the genes that showed the greatest fold changes and those genes had the greatest fold changes due to RXR&#x003b1; deficiency at 6-month old age are listed (tables <xref ref-type="table" rid="T9">9</xref> and <xref ref-type="table" rid="T10">10</xref>). Also at 24-month old, those genes showed the greatest fold change and genes had the greatest fold changes due to hepatocyte RXR&#x003b1; deficiency are listed in Tables <xref ref-type="table" rid="T11">11</xref> and <xref ref-type="table" rid="T12">12</xref>. Surprisingly, the gender-dependent hepatic gene expression was also age-dependent as there was no overlap between the two age groups. Our data indicate that RXR&#x003b1; deficiency affects gender-dependent hepatic gene expression and that this effect is age-dependent.</p><table-wrap position="float" id="T8"><label>Table 8</label><caption><p>Number of cancer-related genes that showed gender-dependent (male vs. female) expression pattern in 6- and 24-month old wild type and hepatocyte RXR&#x003b1;-deficient mice</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Wild Type specific (A)</td><td align="center">RXR&#x003b1; deficiency specific (B)</td><td align="center">Overlap (C)</td><td align="center">Wild type total (A+C)</td><td align="center">RXR&#x003b1; deficiency total (B+C)</td></tr></thead><tbody><tr><td align="center">6-month</td><td align="center">240</td><td align="center">111</td><td align="center">89</td><td align="center">329</td><td align="center">200</td></tr><tr><td align="center">24-month</td><td align="center">76</td><td align="center">116</td><td align="center">51</td><td align="center">127</td><td align="center">167</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T9"><label>Table 9</label><caption><p>Ten gender-dependent genes, which have the greatest fold changes, in wild type and hepatocyte RXR&#x003b1;-deficient 6-month old mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="2">Male <italic>vs</italic>. Female in WT</td><td align="center" colspan="2">Male <italic>vs</italic>. Female in KO</td></tr></thead><tbody><tr><td align="center">Genes in A</td><td align="center">Folds</td><td align="center">Genes in B</td><td align="center">Folds</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">DNAJB1</td><td align="center">26.62</td><td align="center">IL1R1</td><td align="center">31.10</td></tr><tr><td align="center">AFP</td><td align="center">22.52</td><td align="center">SOCS3</td><td align="center">10.63</td></tr><tr><td align="center">ATF3</td><td align="center">19.34</td><td align="center">FMN2</td><td align="center">8.57</td></tr><tr><td align="center">SERPINE1</td><td align="center">14.99</td><td align="center">CXCL14</td><td align="center">6.95</td></tr><tr><td align="center">HSPA1A</td><td align="center">10.99</td><td align="center">CAV1</td><td align="center">6.00</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">PROM1</td><td align="center">-8.55</td><td align="center">WEE1</td><td align="center">-4.98</td></tr><tr><td align="center">CLCA1</td><td align="center">-9.09</td><td align="center">ID4</td><td align="center">-5.50</td></tr><tr><td align="center">DSCR1L1</td><td align="center">-9.17</td><td align="center">PML</td><td align="center">-6.25</td></tr><tr><td align="center">CYP2C19</td><td align="center">-13.83</td><td align="center">GAS1</td><td align="center">-8.93</td></tr><tr><td align="center">PEG3</td><td align="center">-16.00</td><td align="center">PDZRN3</td><td align="center">-10.94</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T10"><label>Table 10</label><caption><p>Top ten gender-dependent cancer-related genes that have the greatest fold change due to hepatocyte RXR&#x003b1; deficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="4">Male <italic>vs</italic>. Female (6 month old mice)</td></tr></thead><tbody><tr><td align="center">Genes in C</td><td align="center">Folds (WT)</td><td align="center">Folds (KO)</td><td align="center">Fold change due to RXR&#x003b1; deficiency</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">MYC</td><td align="center">33.49</td><td align="center">5.52</td><td align="center">6.07</td></tr><tr><td align="center">CDKN1A</td><td align="center">27.04</td><td align="center">5.03</td><td align="center">5.38</td></tr><tr><td align="center">CYP17A1</td><td align="center">-32.26</td><td align="center">-10.32</td><td align="center">3.13</td></tr><tr><td align="center">BTG2</td><td align="center">10.53</td><td align="center">3.48</td><td align="center">3.03</td></tr><tr><td align="center">HSPA1B</td><td align="center">23.96</td><td align="center">8.35</td><td align="center">2.87</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">ABCB1</td><td align="center">-8.77</td><td align="center">-19.23</td><td align="center">0.46</td></tr><tr><td align="center">B4GALNT1</td><td align="center">-2.73</td><td align="center">-6.06</td><td align="center">0.45</td></tr><tr><td align="center">PTP4A3</td><td align="center">-4.33</td><td align="center">-10.67</td><td align="center">0.41</td></tr><tr><td align="center">CXCL2</td><td align="center">2.89</td><td align="center">8.40</td><td align="center">0.34</td></tr><tr><td align="center">HSPB1</td><td align="center">6.40</td><td align="center">19.48</td><td align="center">0.33</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T11"><label>Table 11</label><caption><p>Ten gender-dependent genes, which have the greatest fold changes, in wild type and hepatocyte RXR&#x003b1;-deficient 24-month old mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="2">Male <italic>vs</italic>. Female in WT</td><td align="center" colspan="2">Male <italic>vs</italic>. Female in KO</td></tr></thead><tbody><tr><td align="center">Genes in A</td><td align="center">Folds</td><td align="center">Genes in B</td><td align="center">Folds</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">SNCA</td><td align="center">6.22</td><td align="center">CLEC2D</td><td align="center">45.07</td></tr><tr><td align="center">SOX9</td><td align="center">4.86</td><td align="center">ASNS</td><td align="center">27.09</td></tr><tr><td align="center">CYP26A1</td><td align="center">4.70</td><td align="center">RB1CC1</td><td align="center">11.82</td></tr><tr><td align="center">ABCG2</td><td align="center">4.01</td><td align="center">FMN2</td><td align="center">9.39</td></tr><tr><td align="center">BCL6</td><td align="center">3.46</td><td align="center">RAMP2</td><td align="center">4.13</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">PRLR</td><td align="center">-3.98</td><td align="center">ITGA6</td><td align="center">-5.78</td></tr><tr><td align="center">CXCL10</td><td align="center">-5.29</td><td align="center">DCT</td><td align="center">-6.10</td></tr><tr><td align="center">CD79B</td><td align="center">-7.09</td><td align="center">PSCDBP</td><td align="center">-6.33</td></tr><tr><td align="center">IL7</td><td align="center">-9.71</td><td align="center">PLA2G7</td><td align="center">-6.45</td></tr><tr><td align="center">DSCR1L1</td><td align="center">-10.94</td><td align="center">CD55</td><td align="center">-13.57</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T12"><label>Table 12</label><caption><p>Top ten gender-dependent cancer-related genes that have the greatest fold change due to hepatocyte RXR&#x003b1; deficiency.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="4">Male <italic>vs</italic>. Female</td></tr></thead><tbody><tr><td align="center">Genes in C</td><td align="center">Folds (WT)</td><td align="center">Folds (KO)</td><td align="center">Fold change due to RXR&#x003b1; deficiency</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">SERPINB1</td><td align="center">-9.62</td><td align="center">-2.41</td><td align="center">3.99</td></tr><tr><td align="center">CYP3A4</td><td align="center">-43.86</td><td align="center">-11.68</td><td align="center">3.75</td></tr><tr><td align="center">PROM1</td><td align="center">-6.14</td><td align="center">-3.13</td><td align="center">1.96</td></tr><tr><td align="center">CD74</td><td align="center">-3.86</td><td align="center">-2.02</td><td align="center">1.91</td></tr><tr><td align="center">OSGIN1</td><td align="center">4.45</td><td align="center">2.34</td><td align="center">1.91</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="center">CAV1</td><td align="center">2.14</td><td align="center">3.74</td><td align="center">0.57</td></tr><tr><td align="center">IGHM</td><td align="center">-2.28</td><td align="center">-5.68</td><td align="center">0.40</td></tr><tr><td align="center">S100A8</td><td align="center">-6.80</td><td align="center">-21.10</td><td align="center">0.32</td></tr><tr><td align="center">MT1E</td><td align="center">-2.03</td><td align="center">-6.62</td><td align="center">0.31</td></tr><tr><td align="center">S100A9</td><td align="center">-6.10</td><td align="center">-31.35</td><td align="center">0.19</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Conclusion</title><p>Collectively, RXR&#x003b1; deficiency could lead to significant changes in expression levels of cancer-associated genes in a gender- and age-dependent manner. Overall, there is increased resistance for apoptosis; increased cell migration activity; impaired cell protection ability; compromised cell cycle checkpoint machinery, and elevated inflammatory status. These changes may reflect the deregulation of multiple pathways in liver owing to RXR&#x003b1; deficiency. Although 24 month old hepatocyte RXR&#x003b1;-deficient mice do not develop spontaneous liver cancer, our data implied that hepatocyte RXR&#x003b1;-deficient mice might be more susceptible to cancer development, and this increased risk might be gender- and age-dependent manner.</p><p>The current study provides a database of cancer-related hepatic genes that might contribute to a difference in liver cancer incidence between genders as well as due to aging or retinoid signaling deregulation. The limitation of this study is that the role of those genes associated with liver cancer remains to be characterized in actual liver cancer models, which will be done in our future study.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Animals</title><p>Animal protocols were approved by the institutional animal use committee of the University of Kansas Medical Center, Kansas City. Male and Female C57BL/6J wild type and RXR&#x003b1; knock out mice were weaned at 28 days, housed individually, given free access to water, and randomly assigned to study groups. Four groups of mice were used to determine the effects on gene expression profile at two ages in both male and female mice. Each group had 3 mice. At particular time points after birth, 6 month (mature) and 24 month (aged) mice were sacrificed by cervical dislocation, and the livers were rapidly excised and flash frozen in liquid nitrogen. No signs of pathology were detected in any of the animals used.</p></sec><sec><title>RNA Isolation and Preparation for Microarray Hybridization</title><p>Total RNA was isolated from frozen mouse livers using Trizol Reagent (Invitrogen Corporation, Carlsbad, CA) and further purified using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA). Total RNA was quantified by UV spectrophotometry and its integrity and quality were assessed on RNA 6000 Nano LabChips with the Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA). Total RNA was reverse transcribed into cDNA using reverse transcription kit provided by Invitrogen Company. Synthesis and purification of double-stranded cDNA were conducted as described in the Expression Analysis Technical Manual (Affymetrix, Santa Clara, CA). Biotin-labeled cRNA was synthesized from the purified cDNA using the BioArray High Yield Transcript Labeling Kit according to the manufacturer's specifications (ENZO Life Sciences, Farmingdale, NY). Labeled cRNA was purified using the GeneChip Sample Cleanup Module, quantified by UV spectrophotometry and assessed for quality with the Bioanalyzer 2100. Twenty &#x003bc;g purified cRNA was fragmented and 15 &#x003bc;g fragmented cRNA was hybridized to Affymetrix Mouse Genome 430A 2.0 Array GeneChips (Affymetrix, Santa Clara, CA) according to the Expression Analysis Technical Manual. Washing and staining of the hybridized arrays were carried out using the Fluidics Station 400 and arrays were subsequently scanned with the Hewlett Packard GeneArray Scanner.</p></sec><sec><title>Microarray Data Analysis</title><p>Affymetrix scan data (.cel files) were imported into Rosetta Resolver for analysis (Rosetta Biosoftware, Seattle, WA). Following intrachip normalization and background correction, individual replicates were combined into single "ratio experiments" by an error-weighted method using the control group as a baseline. An agglomerative hierarchical clustering algorithm utilizing an error-weighted Euclidian distance measure was performed on the ratio experiments to identify active genes. Transcripts were defined as active if they increased or decreased by greater than 2.0-fold. The microarray data from this work was submitted to the ArrayExpress database and the accession number is E-MEXP-1711.</p></sec><sec><title>Confirmation of mRNA level changes by quantitative real-time PCR</title><p>The synthesized cDNA was diluted 20 fold by water. All primers and probes were designed based on nucleotide sequences in Genbank using the Primer Express software (PE Applied Biosystems). PCR reaction efficiency was calculated for each primer pair using with five dilution points of the calibrator sample to validate primers and probes. The PCR product covered at least two exons according to introns-exons organisation of selected genes. Each real-time PCR reaction consisted of 1&#x000d7; PCR Master Mix (PE Applied Biosystems), 0.5 &#x003bc;M forward and reverse primers and 1 uM corresponding probe. Final volume is 20 &#x003bc;l. Reactions were carried out on ABI PRISM 7900 real time PCR system (PE Applied Biosystems) for 40 cycles (95&#x000b0;C for 15 s, 60&#x000b0;C for 1 min). The expression fold change for each gene was calculated using the Ct method and &#x003b2;-actin was used as an internal control.</p></sec></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>Professor WYJ designed and supervised the project; HL bred mice and extracted hepatic RNA; GL and LML conducted the microarray experiment; GML performed the data analysis and wrote the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work is supported by NIH grants CA53596, AA12081, AA14147, and COBRE grant P20 RR021940. We thank Ms. Barbara Brede for proofreading of this manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altucci</surname><given-names>L</given-names></name><name><surname>Leibowitz</surname><given-names>MD</given-names></name><name><surname>Ogilvie</surname><given-names>KM</given-names></name><name><surname>de Lera</surname><given-names>AR</given-names></name><name><surname>Gronemeyer</surname><given-names>H</given-names></name></person-group><article-title>RAR and RXR modulation in cancer and metabolic disease</article-title><source>Nature reviews</source><year>2007</year><volume>6</volume><fpage>793</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">17906642</pub-id><pub-id pub-id-type="doi">10.1038/nrd2397</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanamori</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Okuno</surname><given-names>M</given-names></name><name><surname>Matsushima-Nishiwaki</surname><given-names>R</given-names></name><name><surname>Tsurumi</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>S</given-names></name><name><surname>Moriwaki</surname><given-names>H</given-names></name></person-group><article-title>Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells</article-title><source>Cancer science</source><year>2007</year><volume>98</volume><fpage>431</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">17270033</pub-id><pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00384.x</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moriwaki</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Okuno</surname><given-names>M</given-names></name><name><surname>Nishiwaki-Matsushima</surname><given-names>R</given-names></name></person-group><article-title>Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects</article-title><source>Hepatol Res</source><year>2007</year><volume>37 Suppl 2</volume><fpage>S299</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">17877499</pub-id><pub-id pub-id-type="doi">10.1111/j.1872-034X.2007.00201.x</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>YJ</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Lungo</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>P</given-names></name><name><surname>Locker</surname><given-names>J</given-names></name><name><surname>French</surname><given-names>S</given-names></name><name><surname>Sucov</surname><given-names>HM</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice</article-title><source>The Journal of biological chemistry</source><year>2000</year><volume>275</volume><fpage>28285</fpage><lpage>28290</lpage><pub-id pub-id-type="pmid">10866995</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>YJ</given-names></name><name><surname>An</surname><given-names>D</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Repa</surname><given-names>JJ</given-names></name><name><surname>Hung-Po Chen</surname><given-names>T</given-names></name><name><surname>Flores</surname><given-names>M</given-names></name><name><surname>Postic</surname><given-names>C</given-names></name><name><surname>Magnuson</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name><name><surname>French</surname><given-names>S</given-names></name><name><surname>Mangelsdorf</surname><given-names>DJ</given-names></name><name><surname>Sucov</surname><given-names>HM</given-names></name></person-group><article-title>Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver</article-title><source>Molecular and cellular biology</source><year>2000</year><volume>20</volume><fpage>4436</fpage><lpage>4444</lpage><pub-id pub-id-type="pmid">10825207</pub-id><pub-id pub-id-type="doi">10.1128/MCB.20.12.4436-4444.2000</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Kastner</surname><given-names>P</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name></person-group><article-title>Selective ablation of retinoid X receptor alpha in hepatocytes impairs their lifespan and regenerative capacity</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2001</year><volume>98</volume><fpage>4581</fpage><lpage>4586</lpage><pub-id pub-id-type="pmid">11287642</pub-id><pub-id pub-id-type="doi">10.1073/pnas.071056098</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><name><surname>Ao</surname><given-names>Y</given-names></name><name><surname>Konishi</surname><given-names>T</given-names></name><name><surname>Chuang</surname><given-names>KH</given-names></name><name><surname>Lue</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Wan</surname><given-names>YJ</given-names></name></person-group><article-title>Cytochrome P450 genes are differentially expressed in female and male hepatocyte retinoid X receptor alpha-deficient mice</article-title><source>Endocrinology</source><year>2003</year><volume>144</volume><fpage>2311</fpage><lpage>2318</lpage><pub-id pub-id-type="pmid">12746291</pub-id><pub-id pub-id-type="doi">10.1210/en.2002-0129</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>ZJ</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>Zhao</surname><given-names>YL</given-names></name></person-group><article-title>Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia</article-title><source>Chinese medical journal</source><year>2005</year><volume>118</volume><fpage>1093</fpage><lpage>1098</lpage><pub-id pub-id-type="pmid">16098262</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feart</surname><given-names>C</given-names></name><name><surname>Pallet</surname><given-names>V</given-names></name><name><surname>Boucheron</surname><given-names>C</given-names></name><name><surname>Higueret</surname><given-names>D</given-names></name><name><surname>Alfos</surname><given-names>S</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Higueret</surname><given-names>P</given-names></name></person-group><article-title>Aging affects the retinoic acid and the triiodothyronine nuclear receptor mRNA expression in human peripheral blood mononuclear cells</article-title><source>European journal of endocrinology / European Federation of Endocrine Societies</source><year>2005</year><volume>152</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">15757863</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frick</surname><given-names>KM</given-names></name><name><surname>Burlingame</surname><given-names>LA</given-names></name><name><surname>Arters</surname><given-names>JA</given-names></name><name><surname>Berger-Sweeney</surname><given-names>J</given-names></name></person-group><article-title>Reference memory, anxiety and estrous cyclicity in C57BL/6NIA mice are affected by age and sex</article-title><source>Neuroscience</source><year>2000</year><volume>95</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">10619486</pub-id><pub-id pub-id-type="doi">10.1016/S0306-4522(99)00418-2</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>SX</given-names></name><name><surname>Dhahbi</surname><given-names>JM</given-names></name><name><surname>Mote</surname><given-names>PL</given-names></name><name><surname>Spindler</surname><given-names>SR</given-names></name></person-group><article-title>Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><year>2001</year><volume>98</volume><fpage>10630</fpage><lpage>10635</lpage><pub-id pub-id-type="pmid">11535822</pub-id><pub-id pub-id-type="doi">10.1073/pnas.191313598</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The hallmarks of cancer</article-title><source>Cell</source><year>2000</year><volume>100</volume><fpage>57</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10647931</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81683-9</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Lawrence</surname><given-names>T</given-names></name><name><surname>Nizet</surname><given-names>V</given-names></name></person-group><article-title>Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>823</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">16497591</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.016</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harkin</surname><given-names>DP</given-names></name><name><surname>Bean</surname><given-names>JM</given-names></name><name><surname>Miklos</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>YH</given-names></name><name><surname>Truong</surname><given-names>VB</given-names></name><name><surname>Englert</surname><given-names>C</given-names></name><name><surname>Christians</surname><given-names>FC</given-names></name><name><surname>Ellisen</surname><given-names>LW</given-names></name><name><surname>Maheswaran</surname><given-names>S</given-names></name><name><surname>Oliner</surname><given-names>JD</given-names></name><name><surname>Haber</surname><given-names>DA</given-names></name></person-group><article-title>Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1</article-title><source>Cell</source><year>1999</year><volume>97</volume><fpage>575</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">10367887</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80769-2</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Na</surname><given-names>G</given-names></name><name><surname>Jeon</surname><given-names>I</given-names></name><name><surname>Kwon</surname><given-names>YK</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Youn</surname><given-names>H</given-names></name><name><surname>Koo</surname><given-names>Y</given-names></name></person-group><article-title>Glucocorticoids modulate NF-kappaB-dependent gene expression by up-regulating FKBP51 expression in Newcastle disease virus-infected chickens</article-title><source>Molecular and cellular endocrinology</source><year>2007</year><volume>278</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">17870233</pub-id><pub-id pub-id-type="doi">10.1016/j.mce.2007.08.002</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>YF</given-names></name><name><surname>Lin</surname><given-names>WJ</given-names></name><name><surname>Chu</surname><given-names>CY</given-names></name><name><surname>Altuwaijri</surname><given-names>S</given-names></name><name><surname>Wan</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name></person-group><article-title>9-cis-retinoic acid inhibits androgen receptor activity through activation of retinoid X receptor</article-title><source>Molecular endocrinology (Baltimore, Md</source><year>2005</year><volume>19</volume><fpage>1200</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">15650026</pub-id><pub-id pub-id-type="doi">10.1210/me.2004-0181</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>LF</given-names></name><name><surname>Sparks</surname><given-names>A</given-names></name><name><surname>Allende-Vega</surname><given-names>N</given-names></name><name><surname>Xirodimas</surname><given-names>DP</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name><name><surname>Saville</surname><given-names>MK</given-names></name></person-group><article-title>The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2</article-title><source>The EMBO journal</source><year>2007</year><volume>26</volume><fpage>976</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">17290220</pub-id><pub-id pub-id-type="doi">10.1038/sj.emboj.7601567</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graner</surname><given-names>E</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Baron</surname><given-names>A</given-names></name><name><surname>Migita</surname><given-names>T</given-names></name><name><surname>Weinstein</surname><given-names>LJ</given-names></name><name><surname>Lechpammer</surname><given-names>M</given-names></name><name><surname>Huesken</surname><given-names>D</given-names></name><name><surname>Zimmermann</surname><given-names>J</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name></person-group><article-title>The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer</article-title><source>Cancer cell</source><year>2004</year><volume>5</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">15050917</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(04)00055-8</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawighorst</surname><given-names>T</given-names></name><name><surname>Oura</surname><given-names>H</given-names></name><name><surname>Streit</surname><given-names>M</given-names></name><name><surname>Janes</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>LF</given-names></name><name><surname>Oliver</surname><given-names>G</given-names></name><name><surname>Jackson</surname><given-names>DG</given-names></name><name><surname>Detmar</surname><given-names>M</given-names></name></person-group><article-title>Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>7945</fpage><lpage>7956</lpage><pub-id pub-id-type="pmid">12439745</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205956</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Gerard</surname><given-names>RD</given-names></name><name><surname>Li</surname><given-names>XY</given-names></name><name><surname>Alizadeh</surname><given-names>H</given-names></name><name><surname>Niederkorn</surname><given-names>JY</given-names></name></person-group><article-title>Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model</article-title><source>Blood</source><year>1997</year><volume>90</volume><fpage>2738</fpage><lpage>2746</lpage><pub-id pub-id-type="pmid">9326241</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kintscher</surname><given-names>U</given-names></name><name><surname>Goetze</surname><given-names>S</given-names></name><name><surname>Wakino</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Nagpal</surname><given-names>S</given-names></name><name><surname>Chandraratna</surname><given-names>RA</given-names></name><name><surname>Graf</surname><given-names>K</given-names></name><name><surname>Fleck</surname><given-names>E</given-names></name><name><surname>Hsueh</surname><given-names>WA</given-names></name><name><surname>Law</surname><given-names>RE</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes</article-title><source>European journal of pharmacology</source><year>2000</year><volume>401</volume><fpage>259</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">10936484</pub-id><pub-id pub-id-type="doi">10.1016/S0014-2999(00)00461-1</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gopal-Srivastava</surname><given-names>R</given-names></name><name><surname>Cvekl</surname><given-names>A</given-names></name><name><surname>Piatigorsky</surname><given-names>J</given-names></name></person-group><article-title>Involvement of retinoic acid/retinoid receptors in the regulation of murine alphaB-crystallin/small heat shock protein gene expression in the lens</article-title><source>The Journal of biological chemistry</source><year>1998</year><volume>273</volume><fpage>17954</fpage><lpage>17961</lpage><pub-id pub-id-type="pmid">9651402</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.28.17954</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><article-title>[The regulation of vitamin D3 and 9-cis-retinoic acid and their receptors on human hsp90 beta gene]</article-title><source>Zhongguo yi xue ke xue yuan xue bao</source><year>2000</year><volume>22</volume><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">12903442</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rocchi</surname><given-names>P</given-names></name><name><surname>Beraldi</surname><given-names>E</given-names></name><name><surname>Ettinger</surname><given-names>S</given-names></name><name><surname>Fazli</surname><given-names>L</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Nelson</surname><given-names>C</given-names></name><name><surname>Gleave</surname><given-names>M</given-names></name></person-group><article-title>Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis</article-title><source>Cancer research</source><year>2005</year><volume>65</volume><fpage>11083</fpage><lpage>11093</lpage><pub-id pub-id-type="pmid">16322258</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1840</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Tanzer</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>KJ</given-names></name></person-group><article-title>Exogenous androgen treatment delays the stress response following hamster facial nerve injury</article-title><source>Journal of neuroendocrinology</source><year>2007</year><volume>19</volume><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">17425613</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2826.2007.01538.x</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narla</surname><given-names>G</given-names></name><name><surname>Kremer-Tal</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name><name><surname>Kelley</surname><given-names>K</given-names></name><name><surname>Tarocchi</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>SL</given-names></name></person-group><article-title>In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>4428</fpage><lpage>4434</lpage><pub-id pub-id-type="pmid">17297474</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1210223</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzui</surname><given-names>M</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name><name><surname>Lim</surname><given-names>JT</given-names></name><name><surname>Yoshimi</surname><given-names>N</given-names></name><name><surname>Weinstein</surname><given-names>IB</given-names></name></person-group><article-title>Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells</article-title><source>Molecular cancer therapeutics</source><year>2004</year><volume>3</volume><fpage>309</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">15026551</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boiko</surname><given-names>AD</given-names></name><name><surname>Porteous</surname><given-names>S</given-names></name><name><surname>Razorenova</surname><given-names>OV</given-names></name><name><surname>Krivokrysenko</surname><given-names>VI</given-names></name><name><surname>Williams</surname><given-names>BR</given-names></name><name><surname>Gudkov</surname><given-names>AV</given-names></name></person-group><article-title>A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation</article-title><source>Genes &#x00026; development</source><year>2006</year><volume>20</volume><fpage>236</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">16418486</pub-id><pub-id pub-id-type="doi">10.1101/gad.1372606</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Nagano</surname><given-names>T</given-names></name><name><surname>Shah</surname><given-names>Y</given-names></name><name><surname>Cheung</surname><given-names>C</given-names></name><name><surname>Ito</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha</article-title><source>Toxicol Sci</source><year>2008</year><volume>101</volume><fpage>132</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">17690133</pub-id><pub-id pub-id-type="doi">10.1093/toxsci/kfm206</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Moore</surname><given-names>R</given-names></name><name><surname>Goldsworthy</surname><given-names>TL</given-names></name><name><surname>Negishi</surname><given-names>M</given-names></name><name><surname>Maronpot</surname><given-names>RR</given-names></name></person-group><article-title>The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice</article-title><source>Cancer research</source><year>2004</year><volume>64</volume><fpage>7197</fpage><lpage>7200</lpage><pub-id pub-id-type="pmid">15492232</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1459</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>MT</given-names></name><name><surname>Zeng</surname><given-names>S</given-names></name><name><surname>Nie</surname><given-names>D</given-names></name></person-group><article-title>Human pregnane X receptor and resistance to chemotherapy in prostate cancer</article-title><source>Cancer research</source><year>2007</year><volume>67</volume><fpage>10361</fpage><lpage>10367</lpage><pub-id pub-id-type="pmid">17974979</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4758</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desreumaux</surname><given-names>P</given-names></name><name><surname>Dubuquoy</surname><given-names>L</given-names></name><name><surname>Nutten</surname><given-names>S</given-names></name><name><surname>Peuchmaur</surname><given-names>M</given-names></name><name><surname>Englaro</surname><given-names>W</given-names></name><name><surname>Schoonjans</surname><given-names>K</given-names></name><name><surname>Derijard</surname><given-names>B</given-names></name><name><surname>Desvergne</surname><given-names>B</given-names></name><name><surname>Wahli</surname><given-names>W</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name><name><surname>Leibowitz</surname><given-names>MD</given-names></name><name><surname>Colombel</surname><given-names>JF</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies</article-title><source>The Journal of experimental medicine</source><year>2001</year><volume>193</volume><fpage>827</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">11283155</pub-id><pub-id pub-id-type="doi">10.1084/jem.193.7.827</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beigneux</surname><given-names>AP</given-names></name><name><surname>Moser</surname><given-names>AH</given-names></name><name><surname>Shigenaga</surname><given-names>JK</given-names></name><name><surname>Grunfeld</surname><given-names>C</given-names></name><name><surname>Feingold</surname><given-names>KR</given-names></name></person-group><article-title>The acute phase response is associated with retinoid X receptor repression in rodent liver</article-title><source>The Journal of biological chemistry</source><year>2000</year><volume>275</volume><fpage>16390</fpage><lpage>16399</lpage><pub-id pub-id-type="pmid">10747970</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M000953200</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gyamfi</surname><given-names>MA</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>French</surname><given-names>SW</given-names></name><name><surname>Damjanov</surname><given-names>I</given-names></name><name><surname>Wan</surname><given-names>YJ</given-names></name></person-group><article-title>Hepatocyte retinoid X receptor alpha-dependent regulation of lipid homeostasis and inflammatory cytokine expression contributes to alcohol-induced liver injury</article-title><source>The Journal of pharmacology and experimental therapeutics</source><year>2008</year><volume>324</volume><fpage>443</fpage><lpage>453</lpage><pub-id pub-id-type="pmid">17975011</pub-id><pub-id pub-id-type="doi">10.1124/jpet.107.132258</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>MG</given-names></name><name><surname>Miles</surname><given-names>GD</given-names></name><name><surname>Dombkowski</surname><given-names>AA</given-names></name><name><surname>Waxman</surname><given-names>DJ</given-names></name></person-group><article-title>Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver</article-title><source>Molecular endocrinology (Baltimore, Md</source><year>2008</year><volume>22</volume><fpage>1274</fpage><lpage>1286</lpage><pub-id pub-id-type="pmid">18276827</pub-id><pub-id pub-id-type="doi">10.1210/me.2007-0564</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Holvik</surname><given-names>K</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Sogaard</surname><given-names>AJ</given-names></name><name><surname>Haug</surname><given-names>E</given-names></name><name><surname>Falch</surname><given-names>JA</given-names></name></person-group><article-title>Pakistanis living in Oslo have lower serum 1,25-dihydroxyvitamin D levels but higher serum ionized calcium levels compared with ethnic Norwegians. The Oslo Health Study</article-title><source>BMC endocrine disorders</source><year>2007</year><volume>7</volume><fpage>9</fpage><pub-id pub-id-type="pmid">17945003</pub-id><pub-id pub-id-type="doi">10.1186/1472-6823-7-9</pub-id></citation></ref></ref-list></back></article> 